Business
Easton Pharmaceuticals and BMV Medica Close on Joint Distribution Agreement for Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries With Biolyse Pharma Corporation
Easton Pharmaceuticals and BMV Medica Close on Joint Distribution Agreement for Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries With Biolyse Pharma Corporation.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals and BMV Medica Close on Joint Distribution Agreement for Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries With Biolyse Pharma Corporation\n \n \nEaston Pharmaceuticals and BMV Medica Close on Joint Distribution Agreement for Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries With Biolyse Pharma Corporation\n \n TORONTO, ON--(Marketwired - Jun 15, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has closed on the recently announced MOU with BMV Medica S.A. de C.V. to distribute injectable approved cancer drugs from Biolyse Pharma for Mexico and Latin America.\n The Easton / BMV agreement is under similar terms as previously announced with the Common Sense Inc. agreement for the diagnostic women's health products which maintains a 50/50 net profit sharing on all sales of a line of generic cancer drugs beginning with \"Paclitaxel\" and \"Docetaxel\" from St. Catharines, Ontario based Biolyse Pharma Corporation. The terms of the agreement calls for Easton to support the regulatory filings in Mexico for marketing authorization (MA) together with some ancillary costs.\n The regulatory filing process has commenced and Easton has forwarded funds directly to Ackerman Pharma who is overseeing the submission and has received the necessary documents from Biolyse Pharma. Once the completed and translated submission package is ready, it will be put in \"fast-track\" status through a government-approved, third-party authorized reviewer, and if no further documentation is required, the approval could be granted in a few short months. Biolyse's \"Paclitaxel\" is already approved in Canada and several other countries worldwide, and \"Docetaxel\" has been filed for approval with Health Canada.\n The majority of sales in Mexico will be to the Mexican government hospitals and institutions. As Canada is part of the North American Free Trade Agreement (NAFTA), Canadian-manufactured pharmaceuticals qualify for the national tender program in Mexico, providing a major advantage over other non-NAFTA manufacturers. The \"Docetaxel\" market in Mexico is by itself approximately US$15 MM annually, and BMV expects to be able to garner 20% of that within a year of launch, expected in late 2015 or early 2016, growing to 30% within three years. The total gen...